PRESS RELEASE

FOR IMMEDIATE RELEASE

CONTACT

InVitro International

Contact: W. Richard Ulmer

17751 Sky Park East, Suite G

(800) 2-INVITRO

Irvine, CA 92614

http://www.invitrointl.com


INVITRO INTERNATIONAL FY 2009 SALES REACH HIGHEST LEVEL IN 12 YEARS


Irvine, CA January 13, 2010 - Today InVitro International (OTC, Pink Sheets, IVRO) reported FY 2009 sales of $755,513 and net profits of $50,859. These results when compared to FY 2008 were up 8.5% in sales, and 26% lower in profits. IVRO CEO & President, W. Richard Ulmer, summarized the year by saying: "We were very pleased to show a solid sales increase given the conditions of the U.S. and global economies. Such progress, we believe, reflects the increases in non-animal testing in general and more specifically acceptance of our InVitro International offerings. Furthermore, such gains allow us to continue our increased R&D and Regulatory spending. We made good progress in 2009 with our European regulatory submission and acknowledge with much gratitude the contribution made by our partner, ResPharma, in Italy. We remain optimistic regarding both our current and the future acceptance of our now 25 year old company technologies". 

This release may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company's technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.


CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS


Three months ended
September 30

Twelve months ended
September 30


2009

2008

2009

2008

Revenues

215,900

213,386

755,513

696,560

Costs and expenses

237,087

200,493

713,082

640,359

Income (loss) from operations

 (21,187)

 12,892 

42,431

56,201

Other income (loss)

2,698

2,310

8,428

11,230

Net profit (loss)

(18,489)

15,203

50,859

67,431

Profit (loss) per common share

(0.001)

0.001

0.003

0.004

Weighted average common
shares outstanding

16,885,803

16,824,809

16,885,083

16,824,809



CONDENSED CONSOLIDATED BALANCE SHEET

 

 

 

September 30, 2009

September 30, 2008

Cash, cash equivalents and marketable securities

360,660

332,665

Other current assets



204,837

201,949

Total current assets



565,497

534,614

Noncurrent assets



52,886

47,814

Total assets



618,383

582,428

Current liabilities



51,965

74,371

Shareholders' equity



566,418

508,057

Total liabilities and equity



618,383

582,428


# # #

InVitro International
17751 Sky Park East, Suite G
Irvine, CA 92614

800-2-INVITRO (800-246-8487)
949-851-8356 (International callers)
949- 851-4985 Fax

invitro@invitrointl.com

pink sheets quote
Stock Quote, Chart, News

 

 

Recent News
INVITRO INTERNATIONAL REPORTS IMPORTANT FY 2013 & Q1 FY 2014 REGULATORY PROGRESS, SMALL NET PROFITS
 
Order Products Directly!

Purchase Corrositex Database Test Results Online!

 

 

Corrositex Instruction Manual

This manual is password Protected. Please contact InVitro International
in Irvine, CA. for a password.